GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

firsekibart   Click here for help

GtoPdb Ligand ID: 14399

Synonyms: Jin Beixin® (China)
Approved drug
firsekibart is an approved drug
Compound class: Antibody
Comment: Firsekibart (previously genakumab) is an IgG4λ monoclonal antibody that targets interleukin-1β (IL-1β). It was developed for anti-inflammatory potential. Based on peptide sequence matches for the heavy and light variable regions of firsekibart, this appears to be antibody 048Ab-4 (H2L6) in patent CN106928354A [2].
No information available.
Summary of Clinical Use Click here for help
Firsekibart was progressed to clinical trials to determine safety and efficacy as a treatment for gouty arthritis and other chronic infalmmatory indications [3]. First approval was granted by China's NMPA in 2025, to treat gouty arthritis [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07381465 Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus Phase 4 Interventional Chinese SLE Treatment And Research Group
NCT07191444 A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease Observational Ruijin Hospital
NCT05925452 To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. N/A Interventional Changchun GeneScience Pharmaceutical Co., Ltd.
NCT05983445 Safety & Efffficacy of Genakumab in Patients With Frequent Flares Phase 3 Interventional Changchun GeneScience Pharmaceutical Co., Ltd.
NCT05328531 Clinical Study of Genakumab for Injection in Patients With Acute Gout Phase 1/Phase 2 Interventional Changchun GeneScience Pharmaceutical Co., Ltd. 4
NCT05936281 A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) Phase 2 Interventional Changchun GeneScience Pharmaceutical Co., Ltd. 5